Bromide

Bromide

SCHEMBL3286869

Br.CCC1CCOO1.[MgH2]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27626915 0.97
SCHEMBL5945065 0.95
SCHEMBL6467580 0.82
SCHEMBL8196755 0.80
Methyl Alcohol SCHEMBL20875603 0.76
SCHEMBL4612501 0.75
SCHEMBL14678020 0.71
SCHEMBL15738715 0.69
SCHEMBL8234712 0.69
SCHEMBL9050980 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714023-B2 Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites SEPRACOR INC. (US) 2010-05-11 US disclosed
EP-1720541-A1 TREATMENT OR PROPHYLAXIS OF MIGRAINE OR HEADACHE DISORDERS USING CITALOPRAM, ESCITALOPRAM OR CITALOPRAM METABOLITES Sepracor, Inc. (US) 2006-11-15 EP disclosed
US-20050192344-A1 Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites SEPRACOR INC. (US) 2005-09-01 US disclosed
WO-2005079787-A1 TREATMENT OR PROPHYLAXIS OF MIGRAINE OR HEADACHE DISORDERS USING CITALOPRAM, ESCITALOPRAM OR CITALOPRAM METABOLITES SEPRACOR INC. (US) 2005-09-01 WO disclosed
US-20040266864-A1 Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram SEPRACOR INC. 2004-12-30 US disclosed
EP-1446396-A1 METHODS FOR TREATING DEPRESSION AND OTHER CNS DISORDERS USING ENANTIOMERICALLY ENRICHED DESMETHYL- AND DIDESMETHYL-METABOLITES OF CITALOPRAM Sepracor, Inc. (US) 2004-08-18 EP disclosed
WO-2003040121-A1 METHODS FOR TREATING DEPRESSION AND OTHER CNS DISORDERS USING ENANTIOMERICALLY ENRICHED DESMETHYL- AND DIDESMETHYL-METABOLITES OF CITALOPRAM SEPRACOR, INC. (US) 2003-05-15 WO disclosed